Salud financiera de hoja de balance de Ipsen

Salud financiera controles de criterios 6/6

Ipsen tiene unos fondos propios totales de €3.4B y una deuda total de €582.9M, lo que sitúa su ratio deuda/fondos propios en 17.1%. Sus activos y pasivos totales son €6.1B y €2.7B respectivamente. Ipsen El EBIT de la empresa es de €870.9M, por lo que su ratio de cobertura de intereses es de 41.5. Su tesorería e inversiones a corto plazo ascienden a €413.4M.

Información clave

9.6%

Ratio deuda-patrimonio

€368.10m

Deuda

Ratio de cobertura de intereses	44.4x
Efectivo	€528.40m
Patrimonio	€3.82b
Total pasivo	€2.50b
Activos totales	€6.32b

Actualizaciones recientes sobre salud financiera

Recent updates

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Apr 20

There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price

Apr 13

Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Mar 26

Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

Dec 30

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Dec 11

Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?

Sep 28

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Sep 07

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 34% Undervaluation?

Jun 21

Ipsen (EPA:IPN) Is Due To Pay A Dividend Of €1.20

Jun 02

Ipsen's (EPA:IPN) Dividend Will Be €1.20

May 12

Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Mar 19

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Mar 01

Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Jan 19

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

Dec 08

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Nov 02

Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Oct 14

Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

Aug 01

Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Jul 10

Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20

May 26

Ipsen (EPA:IPN) Is Increasing Its Dividend To €1.20

May 04

Ipsen's (EPA:IPN) Dividend Will Be Increased To €1.20

Apr 19

Is Ipsen (EPA:IPN) A Risky Investment?

Apr 18

Here's Why I Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Mar 18

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 50% Undervaluation?

Feb 14

Ipsen (EPA:IPN) Has A Rock Solid Balance Sheet

Nov 04

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Aug 05

Análisis de la situación financiera

Pasivos a corto plazo: IPNLos activos a corto plazo (€1.8B) de la empresa superan a sus pasivos a corto plazo (€1.7B).

Pasivo a largo plazo: IPNLos activos a corto plazo (€1.8B) superan a sus pasivos a largo plazo (€977.5M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: IPN tiene más efectivo que su deuda total.

Reducción de la deuda: IPN ha pasado de 10.9% a 9.6% en los últimos 5 años.

Cobertura de la deuda: IPNLa deuda de la empresa está bien cubierta por el flujo de caja operativo (235.2%).

Cobertura de intereses: IPNLos pagos de intereses de su deuda están bien cubiertos por el EBIT (44.4x cobertura).

Hoja de balance

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de Ipsen

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

Recent updates

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Dividend of €1.20 announced

There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price

Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profit margin trend

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 34% Undervaluation?

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen (EPA:IPN) Is Due To Pay A Dividend Of €1.20

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Upcoming dividend of €1.20 per share at 1.1% yield

Ipsen's (EPA:IPN) Dividend Will Be €1.20

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

First half 2022 earnings released

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types

Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Upcoming dividend of €1.20 per share

Ipsen S.A. Proposes Dividend for the Financial Year 2021, payable on 2 June 2022

Ipsen (EPA:IPN) Is Increasing Its Dividend To €1.20

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for Cabometyx® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Ipsen S.A. Provides Sales Guidance for the Year 2022

Ipsen's (EPA:IPN) Dividend Will Be Increased To €1.20

Is Ipsen (EPA:IPN) A Risky Investment?

Here's Why I Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen S.A. Announces Two-Year Follow-Up Results from Analyses of the Phase III Checkmate -9ER Trial

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 50% Undervaluation?